No abstract

The use of nanocarriers in drug delivery is a breakeven research and has received a clarion call in biomedicine globally. Herein, two newly nano-biomaterials: MCM-41 encapsulated quinine (MCM-41 ⊃ QN) (1) and 3-phenylpropyl silane functionalized MCM-41 loaded QN (pMCM-41 ⊃ QN) (2) were synthesized and well characterized. 1 and 2 along with our two already reported nano-antimalarial drugs (MCM-41 ⊃ ATS) (3) and 3-aminopropyl silane functionalized MCM-41 contained ATS (aMCM-41 ⊃ ATS) (4) were screened in vitro for their activity against P. falciparium W2 strain, cytotoxicity against BGM cells and in vivo for their activity against Plasmodium bergheiNK65. 1 has the highest antimalarial activity in vivo against P. berghei NK65, (ED50: < 0.0625 mg/kg body weight) and higher mean survival time compared to the other nano biomaterials or unencapsulated drugs at doses higher than 0.0625 mg/kg body weight. This encapsulation strategy of MCM-41 ⊃ QN (1) stands very useful and effective in delivering the drug to the target cells compared to other delivery systems and therefore, this encapsulated drug may be considered for rational drug design.

A series of chromium(iii) complexes ligated by N^N^N tridentate 2-quinoxalinyl-6-iminopyridine were synthesized and characterized by elemental analysis and infrared spectroscopy. Single-crystal X-ray diffraction analysis for the structure of complex C3 reveals a distorted octahedral geometry. When methylaluminoxane was employed as the co-catalyst, the chromium complexes showed high activities for ethylene oligomerization and polymerization. The distribution of oligomers obtained followed Schulz–Flory rules with high selectivity for α-olefins. Both steric and electronic effects of coordinated ligands affected the catalytic activities as well as the properties of the catalytic products. The parameters of the reaction conditions were also investigated to explore the optimum catalytic potentials of these complexes.